[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Pinto et al., 2022 - Google Patents

Mechanisms of resistance to second-generation antiandrogen therapy for prostate cancer: actual knowledge and perspectives

Pinto et al., 2022

View HTML
Document ID
15152892874415380968
Author
Pinto F
Dibitetto F
Ragonese M
Bassi P
Publication year
Publication venue
Medical Sciences

External Links

Snippet

Prostate cancer therapy for locally advanced and metastatic diseases includes androgen deprivation therapy (ADT). Second-generation antiandrogens have a role in castration- resistant prostate cancer. Nevertheless, some patients do not respond to this therapy, and …
Continue reading at www.mdpi.com (HTML) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q50/00—Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
    • G06Q50/10—Services
    • G06Q50/22—Health care, e.g. hospitals; Social work
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q50/00—Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
    • G06Q50/01—Social networking
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06F—ELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Hybridisation probes
    • C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06F—ELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/10—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology

Similar Documents

Publication Publication Date Title
Pinto et al. Mechanisms of resistance to second-generation antiandrogen therapy for prostate cancer: actual knowledge and perspectives
Freire et al. The pathway to cancer cachexia: microRNA-regulated networks in muscle wasting based on integrative meta-analysis
Liu et al. Melatonin inhibits androgen receptor splice variant-7 (AR-V7)-induced nuclear factor-kappa B (NF-κB) activation and NF-κB activator-induced AR-V7 expression in prostate cancer cells: potential implications for the use of melatonin in castration-resistant prostate cancer (CRPC) therapy
Benedetti et al. Inhibition of histone demethylases LSD1 and UTX regulates ERα signaling in breast cancer
Yamashita et al. The homeobox only protein homeobox (HOPX) and colorectal cancer
Li et al. Acidosis decreases c-Myc oncogene expression in human lymphoma cells: a role for the proton-sensing G protein-coupled receptor TDAG8
Zheng et al. The crucial role of AR-V7 in enzalutamide-resistance of castration-resistant prostate cancer
Luo et al. MeCP2 promotes colorectal cancer metastasis by modulating ZEB1 transcription
Keup et al. Cell-free DNA variant sequencing using CTC-depleted blood for comprehensive liquid biopsy testing in metastatic breast cancer
Yi et al. Disruption of YY1-EZH2 interaction using synthetic peptides inhibits breast cancer development
Tsujino et al. CRISPR screen contributes to novel target discovery in prostate cancer
Wang et al. Deficiency of NEIL3 enhances the chemotherapy resistance of prostate cancer
Li et al. FBXW7 acts as an independent prognostic marker and inhibits tumor growth in human osteosarcoma
Gaule et al. Dasatinib treatment increases sensitivity to c-met inhibition in triple-negative breast cancer cells
Chang et al. A novel signature of CCNF-associated E3 ligases collaborate and counter each other in breast cancer
Huang et al. Prp19 arrests cell cycle via Cdc5L in hepatocellular carcinoma cells
Jillson et al. Androgen receptor signaling in prostate cancer genomic subtypes
Lim et al. Rosmarinic acid methyl ester regulates ovarian cancer cell migration and reverses cisplatin resistance by inhibiting the expression of Forkhead Box M1
Wickenhauser et al. Tumor microenvironment, HLA class I and APM expression in HPV-negative oral squamous cell carcinoma
Burz et al. Prognosis and Treatment of Gastric Cancer: A 2024 Update
Sundqvist et al. Activation of oncogenic and immune-response pathways is linked to disease-specific survival in Merkel cell carcinoma
Chang et al. Human FBXL8 is a novel E3 ligase which promotes BRCA metastasis by stimulating pro-tumorigenic cytokines and inhibiting tumor suppressors
Jinna et al. Racial disparity in quadruple negative breast cancer: aggressive biology and potential therapeutic targeting and prevention
Siciliano et al. The androgen hormone-induced increase in androgen receptor protein expression is caused by the autoinduction of the androgen receptor translational activity
Buchegger et al. Reprimo, a potential p53-dependent tumor suppressor gene, is frequently hypermethylated in estrogen receptor α-positive breast cancer